Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.
Identifieur interne : 002598 ( PubMed/Curation ); précédent : 002597; suivant : 002599Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.
Auteurs : Y. Pommier [États-Unis] ; G. Kohlhagen ; P. Pourquier ; J M Sayer ; H. Kroth ; D M JerinaSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2000.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : DNA Topoisomerases, Type I, Recombinant Fusion Proteins.
- chemical : 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide, DNA Adducts.
- Animals, Binding Sites, CHO Cells, Cricetinae, Humans, Recombination, Genetic.
Abstract
The catalytic intermediates of DNA topoisomerase I (top1) are cleavage complexes that can relax DNA supercoiling (intramolecular reaction) or mediate recombinations (intermolecular religation). We report here that DNA adducts formed from benzo[a]pyrene bay-region diol epoxides can markedly affect top1 activity. Four oligonucleotide 22-mers of the same sequence were synthesized, each of which contained a stereoisomerically unique benzo[a]pyrene 7, 8-diol 9,10-epoxide adduct at the 2-amino group of a central 2'-deoxyguanosine residue. These four adducts correspond to either cis or trans opening at C-10 of the (+)-(7R, 8S, 9S, 10R)- or (-)-(7S, 8R, 9R, 10S)-7,8-diol 9,10-epoxides. Their solution conformations in duplex DNA (intercalated and minor-groove bound for the cis and trans opened adducts respectively) can be deduced from previous NMR studies. All four adducts completely suppress top1 cleavage activity at the alkylation site and induce the formation of new top1cleavage complexes on both strands of the DNA 3-6 bases away from the alkylation site. The trans opened adduct from the highly carcinogenic (+)-diol epoxide is the most active in inducing top1 cleavage independently of camptothecin, demonstrating that minor groove alkylation can efficiently poison top1. We also found that this isomer of the diol epoxide induces the formation of top1-DNA complexes in mammalian cells, which suggests a possible relationship between induction of top1 cleavage complexes and carcinogenic activity of benzo[a]pyrene diol epoxides.
DOI: 10.1073/pnas.040397497
PubMed: 10688881
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002598
Links to Exploration step
pubmed:10688881Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.</title><author><name sortKey="Pommier, Y" sort="Pommier, Y" uniqKey="Pommier Y" first="Y" last="Pommier">Y. Pommier</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, MD 20892</wicri:regionArea></affiliation></author><author><name sortKey="Kohlhagen, G" sort="Kohlhagen, G" uniqKey="Kohlhagen G" first="G" last="Kohlhagen">G. Kohlhagen</name></author><author><name sortKey="Pourquier, P" sort="Pourquier, P" uniqKey="Pourquier P" first="P" last="Pourquier">P. Pourquier</name></author><author><name sortKey="Sayer, J M" sort="Sayer, J M" uniqKey="Sayer J" first="J M" last="Sayer">J M Sayer</name></author><author><name sortKey="Kroth, H" sort="Kroth, H" uniqKey="Kroth H" first="H" last="Kroth">H. Kroth</name></author><author><name sortKey="Jerina, D M" sort="Jerina, D M" uniqKey="Jerina D" first="D M" last="Jerina">D M Jerina</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10688881</idno><idno type="pmid">10688881</idno><idno type="doi">10.1073/pnas.040397497</idno><idno type="wicri:Area/PubMed/Corpus">002598</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002598</idno><idno type="wicri:Area/PubMed/Curation">002598</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002598</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.</title><author><name sortKey="Pommier, Y" sort="Pommier, Y" uniqKey="Pommier Y" first="Y" last="Pommier">Y. Pommier</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, MD 20892</wicri:regionArea></affiliation></author><author><name sortKey="Kohlhagen, G" sort="Kohlhagen, G" uniqKey="Kohlhagen G" first="G" last="Kohlhagen">G. Kohlhagen</name></author><author><name sortKey="Pourquier, P" sort="Pourquier, P" uniqKey="Pourquier P" first="P" last="Pourquier">P. Pourquier</name></author><author><name sortKey="Sayer, J M" sort="Sayer, J M" uniqKey="Sayer J" first="J M" last="Sayer">J M Sayer</name></author><author><name sortKey="Kroth, H" sort="Kroth, H" uniqKey="Kroth H" first="H" last="Kroth">H. Kroth</name></author><author><name sortKey="Jerina, D M" sort="Jerina, D M" uniqKey="Jerina D" first="D M" last="Jerina">D M Jerina</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide</term><term>Animals</term><term>Binding Sites</term><term>CHO Cells</term><term>Cricetinae</term><term>DNA Adducts</term><term>DNA Topoisomerases, Type I (metabolism)</term><term>Humans</term><term>Recombinant Fusion Proteins (metabolism)</term><term>Recombination, Genetic</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>7,8,8a,9a-Tétrahydro-benzo[10,11]chryséno[3,4-b]oxirène-7,8-diol</term><term>ADN topoisomérases de type I (métabolisme)</term><term>Adduits à l'ADN</term><term>Animaux</term><term>Cellules CHO</term><term>Cricetinae</term><term>Humains</term><term>Protéines de fusion recombinantes (métabolisme)</term><term>Recombinaison génétique</term><term>Sites de fixation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA Topoisomerases, Type I</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide</term><term>DNA Adducts</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ADN topoisomérases de type I</term><term>Protéines de fusion recombinantes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Binding Sites</term><term>CHO Cells</term><term>Cricetinae</term><term>Humans</term><term>Recombination, Genetic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>7,8,8a,9a-Tétrahydro-benzo[10,11]chryséno[3,4-b]oxirène-7,8-diol</term><term>Adduits à l'ADN</term><term>Animaux</term><term>Cellules CHO</term><term>Cricetinae</term><term>Humains</term><term>Recombinaison génétique</term><term>Sites de fixation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The catalytic intermediates of DNA topoisomerase I (top1) are cleavage complexes that can relax DNA supercoiling (intramolecular reaction) or mediate recombinations (intermolecular religation). We report here that DNA adducts formed from benzo[a]pyrene bay-region diol epoxides can markedly affect top1 activity. Four oligonucleotide 22-mers of the same sequence were synthesized, each of which contained a stereoisomerically unique benzo[a]pyrene 7, 8-diol 9,10-epoxide adduct at the 2-amino group of a central 2'-deoxyguanosine residue. These four adducts correspond to either cis or trans opening at C-10 of the (+)-(7R, 8S, 9S, 10R)- or (-)-(7S, 8R, 9R, 10S)-7,8-diol 9,10-epoxides. Their solution conformations in duplex DNA (intercalated and minor-groove bound for the cis and trans opened adducts respectively) can be deduced from previous NMR studies. All four adducts completely suppress top1 cleavage activity at the alkylation site and induce the formation of new top1cleavage complexes on both strands of the DNA 3-6 bases away from the alkylation site. The trans opened adduct from the highly carcinogenic (+)-diol epoxide is the most active in inducing top1 cleavage independently of camptothecin, demonstrating that minor groove alkylation can efficiently poison top1. We also found that this isomer of the diol epoxide induces the formation of top1-DNA complexes in mammalian cells, which suggests a possible relationship between induction of top1 cleavage complexes and carcinogenic activity of benzo[a]pyrene diol epoxides.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10688881</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.</ArticleTitle><Pagination><MedlinePgn>2040-5</MedlinePgn></Pagination><Abstract><AbstractText>The catalytic intermediates of DNA topoisomerase I (top1) are cleavage complexes that can relax DNA supercoiling (intramolecular reaction) or mediate recombinations (intermolecular religation). We report here that DNA adducts formed from benzo[a]pyrene bay-region diol epoxides can markedly affect top1 activity. Four oligonucleotide 22-mers of the same sequence were synthesized, each of which contained a stereoisomerically unique benzo[a]pyrene 7, 8-diol 9,10-epoxide adduct at the 2-amino group of a central 2'-deoxyguanosine residue. These four adducts correspond to either cis or trans opening at C-10 of the (+)-(7R, 8S, 9S, 10R)- or (-)-(7S, 8R, 9R, 10S)-7,8-diol 9,10-epoxides. Their solution conformations in duplex DNA (intercalated and minor-groove bound for the cis and trans opened adducts respectively) can be deduced from previous NMR studies. All four adducts completely suppress top1 cleavage activity at the alkylation site and induce the formation of new top1cleavage complexes on both strands of the DNA 3-6 bases away from the alkylation site. The trans opened adduct from the highly carcinogenic (+)-diol epoxide is the most active in inducing top1 cleavage independently of camptothecin, demonstrating that minor groove alkylation can efficiently poison top1. We also found that this isomer of the diol epoxide induces the formation of top1-DNA complexes in mammalian cells, which suggests a possible relationship between induction of top1 cleavage complexes and carcinogenic activity of benzo[a]pyrene diol epoxides.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pommier</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohlhagen</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pourquier</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sayer</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Kroth</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jerina</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018736">DNA Adducts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>55097-80-8</RegistryNumber><NameOfSubstance UI="D015123">7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.99.1.2</RegistryNumber><NameOfSubstance UI="D004264">DNA Topoisomerases, Type I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015123" MajorTopicYN="Y">7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018736" MajorTopicYN="Y">DNA Adducts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004264" MajorTopicYN="N">DNA Topoisomerases, Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="N">Recombination, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10688881</ArticleId><ArticleId IdType="doi">10.1073/pnas.040397497</ArticleId><ArticleId IdType="pii">040397497</ArticleId><ArticleId IdType="pmc">PMC15750</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anal Biochem. 1975 May 12;65(1-2):125-31</Citation><ArticleIdList><ArticleId IdType="pubmed">1130673</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1998 Oct 1;1400(1-3):83-105</Citation><ArticleIdList><ArticleId IdType="pubmed">9748515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1985 Jun;41(2):541-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2985282</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1985 Nov 25;260(27):14873-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2997227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1988 Apr 1;48(7):1722-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2832051</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1988 Dec 9;16(23):11157-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2849758</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1989 Nov 15;49(22):6318-23</Citation><ArticleIdList><ArticleId IdType="pubmed">2553253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1989 Nov 11;17(21):8521-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2555774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1990 Jul 25;265(21):12529-35</Citation><ArticleIdList><ArticleId IdType="pubmed">2165067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1991 Oct 25;266(30):20418-23</Citation><ArticleIdList><ArticleId IdType="pubmed">1657924</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1991 Dec 5;222(3):669-78</Citation><ArticleIdList><ArticleId IdType="pubmed">1660929</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Res Toxicol. 1989 Sep-Oct;2(5):334-40</Citation><ArticleIdList><ArticleId IdType="pubmed">2519824</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1992 Aug 25;267(24):16755-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1324909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1992 Dec 20;228(4):1025-30</Citation><ArticleIdList><ArticleId IdType="pubmed">1335513</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1993 Jul 15;53(14):3294-301</Citation><ArticleIdList><ArticleId IdType="pubmed">8324741</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7690143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1994 Jan 7;269(1):721-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8276874</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1995 Feb 15;55(4):753-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7850785</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1995 May 15;55(10):2097-103</Citation><ArticleIdList><ArticleId IdType="pubmed">7743509</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1995 May 30;34(21):7200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7766631</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1995 Jun 25;23(12):2314-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7610061</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8861-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7568032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutat Res. 1995 Sep;337(2):135-45</Citation><ArticleIdList><ArticleId IdType="pubmed">7565862</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 1996;65:635-92</Citation><ArticleIdList><ArticleId IdType="pubmed">8811192</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1996 Nov;50(5):1095-102</Citation><ArticleIdList><ArticleId IdType="pubmed">8913340</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Res Toxicol. 1997 Feb;10(2):111-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9049424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Mar 21;272(12):7792-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9065442</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Oct 17;272(42):26441-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9334220</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1997 Oct 28;36(43):13285-91</Citation><ArticleIdList><ArticleId IdType="pubmed">9341219</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1997 Oct 15;57(20):4564-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9377570</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Mar 6;279(5356):1504-13</Citation><ArticleIdList><ArticleId IdType="pubmed">9488644</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Mar 6;279(5356):1534-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9488652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1998 Oct 16;273(42):27245-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9765247</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1999 Jan 12;38(2):569-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9888796</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1999 Mar 1;18(5):1397-406</Citation><ArticleIdList><ArticleId IdType="pubmed">10064605</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Mar 26;274(13):8516-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10085084</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7196-201</Citation><ArticleIdList><ArticleId IdType="pubmed">10377391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Aug 20;274(34):23963-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10446164</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1998 Apr 7;37(14):4993-5000</Citation><ArticleIdList><ArticleId IdType="pubmed">9538018</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 1998 Jun 18;41(13):2216-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9632354</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1998 Jun 23;37(25):9127-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9636059</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1978 Nov;75(11):5358-61</Citation><ArticleIdList><ArticleId IdType="pubmed">281685</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002598 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002598 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:10688881
|texte= Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:10688881" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |